LEADER 02218nam  2200601 a 450 
001 9910456005403321
005 20200520144314.0
010   $a1-280-19299-2
010   $a9786610192991
010   $a0-309-58791-3
010   $a0-585-02541-X
035   $a(CKB)110986584751598
035   $a(SSID)ssj0000137964
035   $a(PQKBManifestationID)11146785
035   $a(PQKBTitleCode)TC0000137964
035   $a(PQKBWorkID)10096668
035   $a(PQKB)10945348
035   $a(MiAaPQ)EBC3376237
035   $a(Au-PeEL)EBL3376237
035   $a(CaPaEBR)ebr10055260
035   $a(OCoLC)923262252
035   $a(EXLCZ)99110986584751598
100   $a19950206d1995      uy             0
101 0 $aeng
135   $aurcn|||||||||
181   $ctxt
182   $cc
183   $acr
200 00$aDevelopment of medications for the treatment of opiate and cocaine addictions$b[electronic resource] $eissues for the government and private sector /$fCarolyn E. Fulco, Catharyn T. Liverman, and Laurence E. Earley, editors ; Committee to Study Medication Development and Research at the National Institute on Drug Abuse, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine
210   $aWashington, DC $cNational Academy Press$d1995
215   $axvii, 250 p. $cill
300   $aCommittee chairman: Laurence E. Earley.
300   $aSupport for this study was provided by the National Institute on Drug Abuse.
311   $a0-309-05244-0 
320   $aIncludes bibliographical references.
606   $aDrug addiction$xTreatment
606   $aCocaine abuse$xTreatment
606   $aSubstance abuse$xTreatment
608   $aElectronic books.
615  0$aDrug addiction$xTreatment.
615  0$aCocaine abuse$xTreatment.
615  0$aSubstance abuse$xTreatment.
676   $a616.86/32061
701   $aFulco$b Carolyn$0905903
701   $aLiverman$b Catharyn T$0879608
701   $aEarley$b Laurence E$0899733
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910456005403321
996   $aDevelopment of medications for the treatment of opiate and cocaine addictions$92243234
997   $aUNINA